These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The effect of benzbromarone on hyperlipidemia in gout].
    Author: Marinchev L, Kŭnev K.
    Journal: Vutr Boles; 1990; 29(5):99-102. PubMed ID: 2080622.
    Abstract:
    It is well known that triglycerides and cholesterol are often increased in gout. In 50% of the patients with hyperuricemia and in 40% of the patients with gout hyperlipidemia is found. K. Kŭnev has found in his former studies that the treatment with the drug Desuric leads to a decrease of cholesterol and other lipids in the blood. The follow up of 38 men with proved gout, mean age 45 years and mean duration of the disease 5 years, established an increase mainly of endogenous triglycerides and cholesterol. Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid. This allows benzbromarone to be recommended for the treatment of hyperlipidemia in gout which will lead to a decrease of the vascular complications and mortality in gout.
    [Abstract] [Full Text] [Related] [New Search]